Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?

Leonardo Roever, Giuseppe Biondi-Zoccai, Sunil V. Rao

Research output: Contribution to journalArticlepeer-review


Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.

Original languageEnglish
Pages (from-to)659-660
Number of pages2
JournalClinical Therapeutics
Issue number3
Publication statusPublished - Mar 1 2017


  • cardiovascular risk
  • dyslipidemia
  • lipids
  • statins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?'. Together they form a unique fingerprint.

Cite this